ISCP Cardiovascular Teams Domains

The Heart Failure CV Team brings together international experts with an interest in the pharmacological management of heart failure across its different phenotypes and stages. The Team will focus on current and emerging therapeutic strategies, optimisation of pharmacotherapy, treatment challenges and areas where evidence needs to be translated into practical clinical application.

The Team will support the development of educational and scientific initiatives addressing real-world challenges in heart failure management, including evidence-based treatment approaches, multimorbidity, patient individualisation and emerging therapies. Its work will aim to facilitate international knowledge exchange and support the appropriate use of cardiovascular pharmacotherapy in patients with heart failure.

The Arrhythmia & Anticoagulation CV Team focuses on pharmacological approaches to cardiac arrhythmias and the prevention of thromboembolic events, with particular attention to areas of evolving evidence and complex clinical decision-making. The Team will explore contemporary approaches to rhythm and rate management, anticoagulation and the optimisation of treatment across diverse patient populations.

Through collaborative scientific and educational activities, the Team will address practical challenges in the management of arrhythmias and anticoagulation, including special populations, treatment selection, drug interactions, balancing thromboembolic and bleeding risks, and the integration of pharmacological and broader clinical strategies.

The Cardio-Kidney-Liver-Metabolic (CKLM) Disorders CV Team addresses the increasingly interconnected nature of cardiovascular, renal, hepatic and metabolic disease. The Team will focus on the complex relationships between these conditions and the implications for cardiovascular risk, disease progression and pharmacological treatment.

The Team will promote a multidisciplinary and integrated approach to pharmacotherapy, addressing treatment challenges arising from multimorbidity, altered drug response, polypharmacy and interactions between cardiovascular and non-cardiovascular therapies. Its activities will aim to support evidence-based, patient-centred approaches across the cardio-renal-metabolic and hepatic spectrum.